TRANSPLANT INDICATIONS and SUCCESS RATES
Lymphoma (Hodgkin and Non-Hodgkin)
- 81 % cure by autologous transplant
- Indicated for relapsed and high-risk lymphomas
Myeloma : 66 % 8 year survival rate by autologous and allogeneic (higher than world average)
- Autologous transplant is the 1st line and most effective treatment, significant prolongation of survival
- Allogeneic transplant is needed for cure
AML (Acute Myeloblastic Leukemia)
- 70% cure by allogeneic transplant
- Doubles cure rate obtained by chemotherapy
- Transplant needed in most patients and is superior to chemotherapy
ALL (Acute Lymphoblastic Leukemia)
- 75% cure, age and cytogenetics affect outcome
Aplastic anemia
- 80-90% cure by allogeneic transplant
MDS / MPD (Myelofibrosis, Polycytemia vera)
- 66% cure by allogeneic transplant, depending on early or late decision
Chronic Leukemias (CML, CLL)
- 80% cure by allogeneic transplant if done at earlier stages of the disease
Germ cell tumors (Testicular and Ovarian cancer)
- 50% 5 year survival rates by autologous transplant
Genetic diseases (Talassemia major / Sickle cell anemia)
- 80 % cure by allogeneic transplant
Multiple Sclerosis
- 70-90 % relapse free survival at 5 years by autologous transplant
Scleroderma (Syslemic Lupus Erythematosus)
- 80-90 % relapse free survival at 5-10 years by autologous transplant
RA (Rheumatoid arthritis)
- Remission can be induced by autologous transplantation
ITP (Idiopathic thrombocytopenic purpura)
- Remission can be induced by autologous transplantation
Survival rates may change by time. Last updated on 10.3.2021